Compare IVVD & THW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IVVD | THW |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 437.1M | 516.7M |
| IPO Year | 2021 | 2015 |
| Metric | IVVD | THW |
|---|---|---|
| Price | $1.22 | $12.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.75 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 86.6K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,426,000.00 | N/A |
| Revenue This Year | $61.57 | N/A |
| Revenue Next Year | $41.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 110.47 | N/A |
| 52 Week Low | $0.49 | $10.13 |
| 52 Week High | $3.07 | $13.19 |
| Indicator | IVVD | THW |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 53.70 |
| Support Level | $1.17 | $12.33 |
| Resistance Level | $1.41 | $12.90 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 36.89 | 51.47 |
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation. The Fund mainly invests in equity and debt securities of public and private U.S. and non-U.S. companies that the Fund's investment adviser believes have the potential for above-average growth. The company's investment portfolio includes holdings across various sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other related areas.